Hemispherx Biopharma Reaches Agreement With FDA on Specific Steps to Achieve Complete NDA on Proposed CFS Treatment Ampligen
...assurances that the FDA will accept the amended NDA for review, and if accepted there are no assurances that the NDA will be approved. About CFS and Ampligen (poly I: Poly C12U), an Experimental Therapeutic A recent independent study enumerated three primary causes of early death in CFS populations...
New Drug Applications (FDA) · More like this

Hemispherx Biopharma Addresses FDA Questions On Ampligen NDA
...Drug Administration ('FDA') detailed responses to all of the 14 questions posed by the FDA concerning the Company's New Drug Application ('NDA') for Ampligen, an experimental therapeutic, to treat Chronic Fatigue Syndrome ('CFS'). Hemispherx received the questions from the FDA on December 5, 2007, at...
New Drug Applications (FDA) · More like this

Hemispherx Biopharma Files New Drug Application for Ampligen as Treatment for Chronic Fatigue Syndrome
Hemispherx Biopharma Files New Drug Application for Ampligen as Treatment for Chronic Fatigue Syndrome NDA of Investigational Drug Includes Four Well-Controlled Trials, More Than 1,200 Trial Subjects and...
New Drug Applications (FDA) · More like this

Having trouble finding what you want?

• Try browsing our A-Z List of Drug Names or our Medical Encyclopedia.
• Try posting your query on the Drugs.com Community Discussion Boards
• Drug Interactions Checker provides detailed information on drug-drug and drug-food interactions.
• Pill Identifier will help you identify an unknown pill by imprint code or shape/color.
• Image Search is helpful if you want to know what a certain pill looks like.
• News, FDA Approvals or In The Pipeline may help if the drug you are looking for is a new drug.